Skip to main content
. 2021 May 26;11(8):2150–2171. doi: 10.1016/j.apsb.2021.05.020

Figure 4.

Figure 4

Non-viral vector-mediated in vivo therapeutic genome editing. (A) Biodegradable LNP encapsulated Cas9 mRNA and sgRNA for TTR disruption in hepatocytes and prolonged reduction of serum TTR in a transthyretin amyloidosis model90. Copyright Cell Press 2018. Under the permission of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). (B) Polymer nanocomplex for Cas9 plasmid DNA delivery for CDK5 disruption treating PD-L1-expressing melanoma and triple-negative breast cancer132. Copyright Elsevier 2020. Under the permission of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). (C) Lipid encapsulated gold NP delivery of sgRNA plasmids and Cas9 protein for Plk1 disruption and melanoma suppression117. Copyright John Wiley and Sons 2017. Under the permission of the Creative Commons Attribution 4.0 international license (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/). (D) Helical polypeptide-based delivery of Cas9/sgRNA expressing plasmids for Plk1 disruption in HeLa cell tumors111. Copyright PNAS 2018. Under the permission of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/).